1298 related articles for article (PubMed ID: 12709465)
21. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.
Sareli P; Radevski IV; Valtchanova ZP; Libhaber E; Candy GP; Den Hond E; Libhaber C; Skudicky D; Wang JG; Staessen JA
Arch Intern Med; 2001 Apr; 161(7):965-71. PubMed ID: 11295959
[TBL] [Abstract][Full Text] [Related]
22. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
23. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents.
Blackburn DF; Lamb DA; Eurich DT; Johnson JA; Wilson TW; Dobson RT; Blackburn JL
J Hypertens; 2007 Jul; 25(7):1499-505. PubMed ID: 17563574
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Holzgreve H; Nakov R; Beck K; Janka HU
Am J Hypertens; 2003 May; 16(5 Pt 1):381-6. PubMed ID: 12745200
[TBL] [Abstract][Full Text] [Related]
25. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen W; Wilson T
Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
[TBL] [Abstract][Full Text] [Related]
26. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Cooper-DeHoff RM; Aranda JM; Gaxiola E; Cangiano JL; Garcia-Barreto D; Conti CR; Hewkin A; Pepine CJ;
Am Heart J; 2006 May; 151(5):1072-9. PubMed ID: 16644338
[TBL] [Abstract][Full Text] [Related]
27. Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Pepine CJ; Kowey PR; Kupfer S; Kolloch RE; Benetos A; Mancia G; Coca A; Cooper-DeHoff RM; Handberg E; Gaxiola E; Sleight P; Conti CR; Hewkin AC; Tavazzi L;
J Am Coll Cardiol; 2006 Feb; 47(3):547-51. PubMed ID: 16458134
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
29. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Devereux RB; Dahlöf B; Kjeldsen SE; Julius S; Aurup P; Beevers G; Edelman JM; de Faire U; Fyhrquist F; Helle Berg S; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
Ann Intern Med; 2003 Aug; 139(3):169-77. PubMed ID: 12899584
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; Ibsen H; Kjeldsen SE; Dahlöf B
Hypertension; 2005 Sep; 46(3):492-9. PubMed ID: 16116047
[TBL] [Abstract][Full Text] [Related]
31. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Brown MJ; Palmer CR; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
Lancet; 2000 Jul; 356(9227):366-72. PubMed ID: 10972368
[TBL] [Abstract][Full Text] [Related]
32. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Frishman WH; Glasser S; Stone P; Deedwania PC; Johnson M; Fakouhi TD
Am J Cardiol; 1999 Feb; 83(4):507-14. PubMed ID: 10073852
[TBL] [Abstract][Full Text] [Related]
33. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Kraiczi H; Hedner J; Peker Y; Grote L
Am J Respir Crit Care Med; 2000 May; 161(5):1423-8. PubMed ID: 10806134
[TBL] [Abstract][Full Text] [Related]
34. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
35. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
36. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ
Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study.
Freytag F; Schelling A; Meinicke T; Deichsel G;
Clin Ther; 2001 Jan; 23(1):108-23. PubMed ID: 11219471
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P
J Am Coll Cardiol; 1998 Nov; 32(5):1228-37. PubMed ID: 9809930
[TBL] [Abstract][Full Text] [Related]
39. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
[TBL] [Abstract][Full Text] [Related]
40. Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
Kribben A; Anlauf M; Distler A; Gärtner H; Holzgreve H; Michaelis J; Röcker L; Schäfers R; Philipp U; Wellek S; Philipp T
Kidney Int Suppl; 1997 Oct; 61():S74-6. PubMed ID: 9328972
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
